ArticleCost effectiveness and resource allocation : C/E2021

Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in china.

Qiaoping Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.